The report provides a detailed analysis essential for establishing an Eletriptan Hydrobromide production plant. It encompasses all critical aspects necessary for Eletriptan Hydrobromide production, including the cost of Eletriptan Hydrobromide production, Eletriptan Hydrobromide plant cost, Eletriptan Hydrobromide production costs, and the overall Eletriptan Hydrobromide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Eletriptan Hydrobromide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Eletriptan Hydrobromide is an active pharmaceutical ingredient primarily used in the pharmaceutical industry for the acute treatment of migraine headaches in adults. It acts as a selective serotonin 5-HT1B/1D receptor agonist, which helps relieve migraine symptoms by constricting dilated cerebral blood vessels and inhibiting the release of pro-inflammatory neuropeptides from sensory nerve endings.
It is not used for migraine prevention or for certain types of migraines, like hemiplegic or cluster headaches. Eletriptan is widely formulated into oral tablets and orodispersible tablets for patient use, emphasising its important role in migraine therapy.
The market drivers for Eletriptan Hydrobromide revolve around the rising global prevalence of migraine disorders, which affects 10-12% of the population, creating sustained demand for effective acute migraine treatments. Increased healthcare expenditure worldwide, especially in developing economies, and growing awareness among patients and healthcare professionals about migraine management and treatment options boost market growth.
The industry benefits from ongoing innovations in formulation, such as extended-release and orodispersible tablets, as well as the development of combination therapies and personalised medicine approaches. The expansion of telemedicine and online pharmaceutical sales channels also facilitates easier access to Eletriptan, further driving demand. However, industrial eletriptan hydrobromide procurement is influenced by generic competition post-patent expiry, which leads to price erosion but also wider availability and affordability.
Raw Material for Eletriptan Hydrobromide Production
According to the Eletriptan Hydrobromide production plant project report, the raw material for Eletriptan Hydrobromide production includes methanesulphonic acid.
Manufacturing Process of Eletriptan Hydrobromide
The extensive Eletriptan Hydrobromide production cost report consists of the following major industrial production process:
- Production via hydrolysation: The production process of Eletriptan Hydrobromide involves hydrolysing a specific indole derivative, followed by reduction using a metal catalyst and methanesulphonic acid to form Eletriptan methanesulphonate. This intermediate is then treated with a base to release the free compound, which is extracted into an organic solvent. The organic layer may be purified via silica gel chromatography before solvent evaporation to yield a residue. This residue is dissolved in another solvent, and aqueous hydrobromic acid is added to produce Eletriptan Hydrobromide, resulting in a purified pharmaceutical-grade salt ready for formulation.
Properties of Eletriptan Hydrobromide
Eletriptan Hydrobromide is a white to pale tan powder with the molecular formula C22H26N2O2S·HBr and a molecular weight of 463.43. It is readily soluble in water and DMSO. It is an indole derivative acting as a selective 5-HT1B/1D receptor agonist used for migraine treatment. Its melting point is around 169-171 degree Celsius. The compound has a polar surface area of about 53.17 Ų with moderate hydrogen-bond donors and acceptors, and six rotatable bonds. It is stable under standard storage conditions, typically kept in a dark, inert atmosphere at low temperatures in a desiccated environment. Eletriptan Hydrobromide is biologically active as a serotonin agonist and functions to constrict cerebral blood vessels and inhibit pro-inflammatory neuropeptide release.
